• Increasing access to care by limiting step therapy. Safe Step Act HR 2630, S 652. Lowering out-of-pocket costs for patients. HELP Copays Act HR830, S1375 HHS response to HIV+Hep vs Baccerra law suit. FY 2025 HHS Notice of Benefit Payments and Parameters, copay assistance. Pharmacy Benefit Manager Reform. PBM Transparency Act S 127; Prescription Pricing for the People Act S 113; PBM Reform Act, S. 1339; Hidden Fee Disclosure Act HR 4508. Funding for medical research and education at the NIH and CDC. NIH OADR RFI response. Biosimliar interchageability.
• HHS FY 2025 NBPP, as relates to copay accumulators.

Duration: January 1, 2023 to present

General Issues: Health Issues, Medicare/Medicaid

Spending: about $250,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2023: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Centers For Disease Control & Prevention (CDC)